Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Reply to: Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer.

Doulami G, Theodorou D.

Clin Oncol (R Coll Radiol). 2011 Nov;23(9):653; author reply 653. doi: 10.1016/j.clon.2011.07.004. Epub 2011 Jul 28. No abstract available.

PMID:
21798730
2.

Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer.

Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T.

Clin Oncol (R Coll Radiol). 2011 Apr;23(3):182-8. doi: 10.1016/j.clon.2010.12.001. Epub 2011 Jan 12.

PMID:
21232928
3.

Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.

Luu TD, Gaur P, Force SD, Staley CA, Mansour KA, Miller JI Jr, Miller DL.

Ann Thorac Surg. 2008 Apr;85(4):1217-23; discussion 1223-4. doi: 10.1016/j.athoracsur.2007.11.070.

PMID:
18355499
4.

[Effectiveness and safety of chemoradiation in a community-based population of patients with esophageal cancer].

Goto A, Hasegawa Y, Sukawa Y, Fujii K, Matunaga Y, Suzuki K, Yonezawa K, Abe T, Wakasugi H, Itoh M, Itoh A, Shinomura Y, Kagei K.

Gan To Kagaku Ryoho. 2010 Nov;37(11):2115-9. Japanese.

PMID:
21084810
5.

Oesophageal cancer treatment in a tertiary referral hospital evaluated by indicators for quality of care.

Courrech Staal EF, Bloemendal KM, Bloemer MC, Aleman BM, Cats A, van Sandick JW.

Eur J Surg Oncol. 2012 Feb;38(2):150-6. doi: 10.1016/j.ejso.2011.11.006. Epub 2011 Dec 3.

PMID:
22136801
6.

Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?

Barthel JS, Kucera ST, Lin JL, Hoffe SE, Strosberg JR, Ahmed I, Dilling TJ, Stevens CW.

Gastrointest Endosc. 2010 Feb;71(2):235-40. doi: 10.1016/j.gie.2009.09.038. Epub 2009 Dec 8.

PMID:
20003971
7.

Treatment of locally advanced esophageal cancer with surgery and chemoradiation.

Siersema PD, van Hillegersberg R.

Curr Opin Gastroenterol. 2008 Jul;24(4):535-40. doi: 10.1097/MOG.0b013e3283025ca2. Review.

PMID:
18622172
8.

Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer.

Odelli C, Burgess D, Bateman L, Hughes A, Ackland S, Gillies J, Collins CE.

Clin Oncol (R Coll Radiol). 2005 Dec;17(8):639-45.

PMID:
16372491
9.

Prognostic factors in patients with esophageal carcinoma treated with chemoradiation: single center experience.

Cincibuch J, Neoral C, Aujeský R, Srámek V, Schneiderka P, Studentová H, Melichar B, Kohoutek M, Stráznická J, Vrba R, Juránová J, Flodr P, Machácek J, Cwiertha K.

Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1145-9.

PMID:
21410047
11.

Chemo-radiotherapy in locally advanced squamous cell oesophageal cancer--are upper third tumours more responsive?

Papp A, Cseke L, Farkas R, Pavlovics G, Horvath G, Varga G, Szigeti A, Bellyei S, Marton S, Poto L, Kalmar K, Vereczkei A, Pozsgai E, Horvath OP.

Pathol Oncol Res. 2010 Jun;16(2):193-200. doi: 10.1007/s12253-009-9206-5. Epub 2009 Sep 17.

PMID:
19760123
12.

Combined modality therapy of esophageal cancer--standard of care?

Urba S.

Surg Oncol Clin N Am. 2002 Apr;11(2):377-86. Review.

PMID:
12424857
13.

Stage-specific therapy for cancer of the oesophagus: a new 'cancer of the elderly'.

Krasna MJ.

Drugs Aging. 2009;26(3):185-94. doi: 10.2165/00002512-200926030-00001.

PMID:
19358615
14.

A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone.

Kesler KA, Helft PR, Werner EA, Jain NP, Brooks JA, DeWitt JM, Leblanc JK, Fineberg NS, Einhorn LH, Brown JW.

Ann Thorac Surg. 2005 Apr;79(4):1116-21.

PMID:
15797035
15.

Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer?

Imdahl A, Jenkner J, Ihling C, Rückauer K, Farthmann EH.

Am J Surg. 2000 Jun;179(6):514-20.

PMID:
11004343
16.

Changes in diagnostic and treatment strategies of oesophageal cancer in the period from 2001 to 2009: a survey in the Netherlands.

Homs MY, van Oijen MG, Wijnhoven BP, van Hillegersberg R, de Boer-Dennert M, Siersema PD.

Eur J Gastroenterol Hepatol. 2012 Feb;24(2):126-33. doi: 10.1097/MEG.0b013e32834e7f29.

PMID:
22113210
17.

Clinical aspects of multimodality therapy for resectable locoregional esophageal cancer.

Shinoda M, Hatooka S, Mori S, Mitsudomi T.

Ann Thorac Cardiovasc Surg. 2006 Aug;12(4):234-41. Review.

PMID:
16977291
18.

Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma.

Morgan MA, Lewis WG, Casbard A, Roberts SA, Adams R, Clark GW, Havard TJ, Crosby TD.

Br J Surg. 2009 Nov;96(11):1300-7. doi: 10.1002/bjs.6705.

PMID:
19847875
19.

Measurement of outcome.

Blazeby JM.

Surg Oncol. 2001 Nov;10(3):127-33.

PMID:
11750232
20.

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C.

J Clin Oncol. 2007 Apr 1;25(10):1160-8.

PMID:
17401004

Supplemental Content

Support Center